Surface Oncology, Inc.

NasdaqCM:SURF Stock Report

Market Cap: US$65.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Surface Oncology Management

Management criteria checks 3/4

Surface Oncology's CEO is Rob Ross, appointed in Apr 2021, has a tenure of 2.42 years. total yearly compensation is $1.92M, comprised of 29.5% salary and 70.5% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth $89.02K. The average tenure of the management team and the board of directors is 2.4 years and 4.7 years respectively.

Key information

Rob Ross

Chief executive officer

US$1.9m

Total compensation

CEO salary percentage29.5%
CEO tenure2.4yrs
CEO ownership0.1%
Management average tenure2.4yrs
Board average tenure4.7yrs

Recent management updates

Recent updates

Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically

Nov 07
Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically

Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts

Aug 08
Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts

Surface Oncology GAAP EPS of -$0.46 misses by $0.01

Aug 03

Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline

May 25

News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

May 11
News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Feb 23
Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I

Jan 18

Is Surface Oncology (NASDAQ:SURF) A Risky Investment?

Nov 11
Is Surface Oncology (NASDAQ:SURF) A Risky Investment?

Surface Oncology: Staying The Course

Oct 24

Surface Oncology: A Diverse, But Early Pipeline

Jul 13

Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?

Jun 07
Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?

Surface Oncology EPS beats by $0.04, beats on revenue

May 05

Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like

Mar 15
Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Feb 16
Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Surface Oncology: Early Stage Cancer-Specific Company With Novel Assets

Dec 09

What Kind Of Shareholders Hold The Majority In Surface Oncology, Inc.'s (NASDAQ:SURF) Shares?

Dec 08
What Kind Of Shareholders Hold The Majority In Surface Oncology, Inc.'s (NASDAQ:SURF) Shares?

Surface Oncology shares rise 13% on Fast Track tag for SRF388

Nov 11

CEO Compensation Analysis

How has Rob Ross's remuneration changed compared to Surface Oncology's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-US$93m

Mar 31 2023n/an/a

-US$90m

Dec 31 2022US$2mUS$568k

-US$64m

Sep 30 2022n/an/a

-US$66m

Jun 30 2022n/an/a

-US$63m

Mar 31 2022n/an/a

-US$57m

Dec 31 2021US$5mUS$506k

-US$78m

Sep 30 2021n/an/a

US$13m

Jun 30 2021n/an/a

US$17m

Mar 31 2021n/an/a

US$21m

Dec 31 2020US$1mUS$435k

US$59m

Sep 30 2020n/an/a

-US$24m

Jun 30 2020n/an/a

-US$25m

Mar 31 2020n/an/a

-US$28m

Dec 31 2019US$810kUS$400k

-US$55m

Sep 30 2019n/an/a

-US$44m

Jun 30 2019n/an/a

-US$44m

Mar 31 2019n/an/a

-US$35m

Dec 31 2018US$880kUS$361k

-US$7m

Sep 30 2018n/an/a

-US$18m

Jun 30 2018n/an/a

-US$15m

Mar 31 2018n/an/a

-US$13m

Dec 31 2017US$467kUS$329k

-US$45m

Compensation vs Market: Rob's total compensation ($USD1.92M) is above average for companies of similar size in the US market ($USD763.55K).

Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.

CEO

Rob Ross (49 yo)

2.4yrs

Tenure

US$1,924,455

Compensation

Dr. Robert W. Ross, also known as Rob, M.D., is President, Chief Executive Officer and Director at Surface Oncology, Inc since April 01, 2021. He serves as Independent Director at Xilio Therapeutics, Inc....

Leadership Team

NamePositionTenureCompensationOwnership
Robert Ross
President2.4yrsUS$1.92m0.14%
$ 89.0k
Alison O'Neill
Chief Medical Officer3.6yrsUS$1.06mno data
Jessica Fees
CFO & Treasurer4.8yrsno data0.17%
$ 109.1k
Chandra Adams
Deputy General Counsel & Secretaryless than a yearno data0.051%
$ 33.1k
Lisa McGrath
Chief People Officerno datano datano data
Shannon Devens
Senior Vice President of Development Operations1.8yrsno datano data

2.4yrs

Average Tenure

52yo

Average Age

Experienced Management: SURF's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robert Ross
President2.4yrsUS$1.92m0.14%
$ 89.0k
Charles Sigal
Independent Member of Scientific Advisory Board & Director5.6yrsUS$80.57k0.075%
$ 48.6k
David Grayzel
Independent Director9.4yrsUS$84.57k0%
$ 0
J. Goater
Director5.6yrsUS$72.57k0.21%
$ 138.3k
Alexander Rudensky
Member of Scientific Advisory Board4.7yrsno datano data
Armen Shanafelt
Independent Director8.8yrsUS$89.07k0%
$ 0
Laurie Stelzer
Independent Director5.6yrsUS$92.57k0%
$ 0
F. Hodi
Member of Scientific Advisory Boardno datano datano data
Denice Torres
Independent Chairman & Lead Independent Director2.2yrsUS$151.82k0%
$ 0
Christopher Hunter
Member of Scientific Advisory Board4.7yrsno datano data
Carla Rothlin
Member of Scientific Advisory Board4.7yrsno datano data
Arlene Sharpe
Member of Scientific Advisory Board4.7yrsno datano data

4.7yrs

Average Tenure

55yo

Average Age

Experienced Board: SURF's board of directors are considered experienced (4.7 years average tenure).